ReviewViruses2021
Research Progress and Challenges in Vaccine Development against Classical Swine Fever Virus.
Review in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- The tip of the iceberg: high-risk contacts for hemorrhagic fevers of swine in the Caribbean.Veterinary research · 2026Article
- Efficacy Evaluation of an E2 Subunit Vaccine Against Highly Virulent Classical Swine Fever Virus Strain.Vaccines · 2025Article
- Article
- A single-dose mRNA vaccine encoding the classical swine fever virus E2-ECD induces durable protective immunity in rabbits.Veterinary research · 2025Article
- Classical swine fever virus utilizes stearoyl-CoA desaturase 1-mediated lipid metabolism to facilitate viral replication.Journal of virology · 2025Article
- Protective Efficacy of a ChimericViruses · 2025Article
- Molecular breeding of pigs in the genome editing era.Genetics, selection, evolution : GSE · 2025Review
- Enhancement of immune responses to classical swine fever virus E2 in mice by fusion or mixture with the porcine IL-28B.Applied microbiology and biotechnology · 2025Article
- Comprehensive evaluation of transgenic rice lines expressing CSFV E2 protein in genetic stability, environmental safety and field adaptation.Frontiers in plant science · 2025Article
- Circular mRNA-LNP vaccine encoding self-assembled E2-TMD-mi3 nanoparticles licit enhanced CSFV-specific immunity over commercial subunit vaccine.Frontiers in immunology · 2025Article
- Viral Live-Attenuated Vaccines (LAVs): Past and Future Directions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Development of classical swine fever virus E2-protein based indirect ELISA for detection of antibodies against the virus in pigs.Veterinary research communications · 2024Article
- Article
- Safety and DIVA Capability of Novel Live Attenuated Classical Swine Fever Marker Vaccine Candidates in Pregnant Sows.Viruses · 2024Article
- Ferritin Nanoparticle Delivery of the E2 Protein of Classical Swine Fever Virus Completely Protects Pigs from Lethal Challenge.Vaccines · 2024Article
- Monitoring and evaluation of provincial classical swine fever immunization implementation with an E2 subunit vaccine in Jeju Island, South Korea.Clinical and experimental vaccine research · 2024Article
- Safety and Immunogenicity of ChimericVaccines · 2023Article
- Development of short hairpin RNA expression vectors targeting the internal ribosomal entry site of the classical swine fever virus genomic RNA.BMC biotechnology · 2023Article
- Article
- Rapid Identification of ASFV, CSFV and FMDV from Mongolian Outbreaks with MinION Short Amplicon Sequencing.Pathogens (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classical swine fever (CSF), caused by CSF virus (CSFV), is one of the most devastating viral epizootic diseases of swine in many countries. To control the disease, highly efficacious and safe live attenuated vaccines have been used for decades. However, the main drawback of these conventional vaccines is the lack of differentiability of infected from vaccinated animals (DIVA concept). Advances in biotechnology and our detailed knowledge of multiple basic science disciplines have facilitated the development of effective and safer DIVA vaccines to control CSF. To date, two types of DIVA vaccines have been developed commercially, including the subunit vaccines based on CSFV envelope glycoprotein E2 and chimeric pestivirus vaccines based on infectious cDNA clones of CSFV or bovine viral diarrhea virus (BVDV). Although inoculation of these vaccines successfully induces solid immunity against CSFV, none of them could ideally meet all demands regarding to safety, efficacy, DIVA potential, and marketability. Due to the limitations of the available choices, researchers are still striving towards the development of more advanced DIVA vaccines against CSF. This review summarizes the present status of candidate CSFV vaccines that have been developed. The strategies and approaches revealed here may also be helpful for the development of new-generation vaccines against other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.